Back

A combined risk model shows viability for personalized breast cancer risk assessment in the Indonesian population

Rabbani, B.; Tanu, S. G.; Ramanto, K. N.; Audrienna, J.; Sodiqi, F. A.; Fernandez, E. A.; Gonzalez-Porta, M.; Valeska, M. D.; Haruman, J.; Ulag, L. H.; Maulana, Y.; Junusmin, K. I.; Amelia, M.; Gabriella, G.; Soetyono, F.; Fajarrahman, A.; Maudani, S. S.; Agatha, F. A.; Wijaya, M.; Br Sormin, S. T.; Sani, L.; Ali, S.; Winata, A.; Salim, A.; Irwanto, A.; Haryono, S. J.

2023-09-24 oncology
10.1101/2023.09.22.23295602
Show abstract

Breast cancer remains a significant concern worldwide, with a rising incidence in Indonesia. This study aims to evaluate the applicability of risk-based screening approaches in the Indonesian demographic through a case-control study involving 305 women. We developed a personalized breast cancer risk assessment workflow that integrates multiple risk factors, including clinical (Gail) and polygenic (Mavaddat) risk predictions, into a consolidated risk category. By evaluating the area under the receiver operating characteristic curve (AUC) of each single-factor risk model, we demonstrate that they retain their predictive accuracy in the Indonesian context (AUC for clinical risk: 0.67 [0.61,0.74]; AUC for genetic risk: 0.67 [0.61,0.73]). Notably, our combined risk approach enhanced the AUC to 0.70 [0.64,0.76], highlighting the advantages of a multifaceted model. Our findings demonstrate for the first time the applicability of the Mavaddat and Gail models to Indonesian populations, and show that within this demographic, combined risk models provide a superior predictive framework compared to single-factor approaches.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
PLOS ONE
based on 1737 papers
Top 20%
18.6%
2
Breast Cancer Research
based on 11 papers
Top 0.1%
7.0%
3
Scientific Reports
based on 701 papers
Top 26%
7.0%
4
Cancers
based on 57 papers
Top 3%
5.8%
5
Cancer Medicine
based on 17 papers
Top 0.4%
5.1%
6
Diagnostics
based on 36 papers
Top 0.5%
4.9%
7
Nature Communications
based on 483 papers
Top 19%
3.2%
50% of probability mass above
8
PeerJ
based on 46 papers
Top 0.9%
3.2%
9
British Journal of Cancer
based on 22 papers
Top 1%
3.1%
10
eLife
based on 262 papers
Top 6%
3.1%
11
Frontiers in Oncology
based on 34 papers
Top 3%
3.1%
12
JCO Clinical Cancer Informatics
based on 14 papers
Top 0.7%
3.1%
13
Cancer Epidemiology, Biomarkers & Prevention
based on 14 papers
Top 0.9%
2.7%
14
PLOS Computational Biology
based on 141 papers
Top 6%
2.0%
15
JAMA Network Open
based on 125 papers
Top 12%
1.4%
16
BMC Research Notes
based on 11 papers
Top 0.1%
1.4%
17
International Journal of Cancer
based on 18 papers
Top 1%
1.4%
18
npj Precision Oncology
based on 14 papers
Top 3%
1.3%
19
iScience
based on 74 papers
Top 5%
1.3%
20
BMC Cancer
based on 21 papers
Top 4%
0.9%
21
Clinical Cancer Research
based on 22 papers
Top 4%
0.9%
22
JCO Precision Oncology
based on 11 papers
Top 2%
0.9%
23
International Journal of Radiation Oncology*Biology*Physics
based on 13 papers
Top 2%
0.9%
24
International Journal of Epidemiology
based on 65 papers
Top 9%
0.7%
25
eClinicalMedicine
based on 55 papers
Top 6%
0.7%
26
BMJ Open
based on 553 papers
Top 51%
0.7%